trial · primary record
Belinostat
Carcinoma, Neuroendocrine
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2028-07-30 |
| Primary endpoint | To determine if pharmacogenomic intervention can normalize the area under the curve (AUC) at cycle 6 between UGT1A1*28 and UGT1A1*60 genotypes) of belinostat administered as a continuous 48 h infusion in combination with cisplatin and etoposide |
| Registry ID | NCT06406465 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:43.289Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06406465
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.